Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse

Phase 2

Recruiting

• Conditions: High-risk acute leukemia patients; Cancer - Leukaemia - Acute leukaemia

• Registration Number: ACTRN12608000129381
• Lead Sponsor: Huisheng Ai

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-03-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

High risk leukemia patients

Exclusion Criteria

The patients with blast cells is over 50% in bone marrow after chemotherapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Transplant ralated mortality, include conditioning complication and severe infection[1 year];Incidence of graft-versus-host disease,include acute and chronic GVHD[1 year];Survival[1 year]

Secondary Outcome Measures

Name	Time	Method
Overall survival:from treatment begining to search time point[3 years];Leukemia relapse rates[3 years]